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Abstract
Background: Dementia, with Alzheimer’s disease (AD) being the most common form, is a major hip fracture risk
factor, but currently it is not known whether the same factors predict hip fracture among persons with and
without dementia/AD. We compared the predictors of hip fracture and mortality after hip fracture in persons
with and without AD.
Methods: An exposure-matched cohort of all community-dwellers of Finland who received a new clinically
verified AD diagnosis in 2005–2011 and had no history of previous hip fracture (N = 67,072) and an age,
sex, and region-matched cohort of persons without AD (N = 67,072). Associations between sociodemographic
characteristics, comorbidities and medications and risk of hip fracture and mortality after hip fracture were
assessed with Cox regression.
Results: As expected, the incidence of hip fractures in 2005–2012 (2.19/100 person-years vs 0.90/100 person-
years in the non-AD cohort), as well as mortality after hip fracture (29/100 person-years vs 23/100 person-
years in the non-AD cohort) were higher in the AD cohort. This difference was evident regardless of the risk
factors. Mental and behavioural disorders (adjusted hazard ratio; HR 95% confidence interval CI: 1.16, 1.09-1.24
and 1.71, 1.52-1.92 in the AD and non-AD-cohorts), antipsychotics (1.12, 1.04-1.20 and 1.56, 1.38-1.76 for AD
and non-AD-cohorts) and antidepressants (1.06, 1.00-1.12 and 1.34 1.22-1.47 for AD and non-AD-cohorts) were
related to higher, and estrogen/combination hormone therapy (0.87, 0.77-0.9 and 0.79, 0.64-0.98 for AD and
non-AD-cohorts) to lower hip fracture risk in both cohorts. Stroke (1.42, 1.26-1.62), diabetes (1.13, 0.99-1.28),
active cancer treatment (1.67, 1.22-2.30), proton pump inhibitors (1.14, 1.05-1.25), antiepileptics (1.27, 1.11-1.46)
and opioids (1.10, 1.01-1.19) were associated with higher hip fracture risk in the non-AD cohort. Similarly, the
associations between mortality risk factors (age, sex, several comorbidities and medications) were stronger in
the non-AD cohort.
Conclusions: AD itself appears to be such a significant risk factor for hip fracture, and mortality after hip
fracture, that it overrules or diminishes the effect of other risk factors. Thus, it is important to develop and
implement preventive interventions that are suitable and effective in this population.
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Background
Alzheimer’s disease (AD), the most common form of de-
mentia, is a key determinant of healthcare costs and
health-related quality of life [1]. This is partially due to
higher risk of falls and hip fractures among persons with
AD [2, 3]. Regardless of cognitive status, hip fracture has
been associated with higher mortality, loss of function
and mobility [2], but persons with AD have been shown
to have an increased risk of death after hip fracture in
comparison to those without AD [4]. Similarly, people
with dementia have higher risk of institutionalisation or
death after hip fracture [5]. Therefore, it is important to
identify modifiable risk factors that could be targeted in
order to decrease the incidence of hip fractures. As vari-
ous measures for preventing falls and hip fractures are
available [6–11], it is also important to identify non-
modifiable risk factors, as they would aid in targeting
these interventions to high-risk persons.
Previous studies have shown that women and older
individuals have a higher risk of hip fracture [12]. In
addition to AD, other comorbidities including previous
hip fractures [13], stroke [14], chronic obstructive pul-
monary disease (COPD) [15] and other pulmonary dis-
eases [12, 16], diabetes [13, 17], and cardiovascular
diseases [12] increase the susceptibility to hip fracture.
In addition, various medications such as analgesics, gas-
troprotectants and different cardiovascular medications,
antidepressants, antipsychotics, antiepileptics and COPD
medications have been associated with increased hip
fracture risk [4, 18, 19]. Similarly, higher age [20] and
comorbidities such as cancer, ischaemic heart disease,
malignant cancer, diabetes [21, 22] are related to higher
mortality after hip fracture. Although women have
higher risk of hip fracture, they have been shown to have
lower risk of death after hip fracture [20, 21, 23].
However, none of these studies have assessed whether
the same factors are associated with hip fracture risk, or
mortality after hip fracture among persons with AD, who
are particularly susceptible to hip fracture. Therefore, we
compared the predictors of hip fracture and mortality
after hip fracture in persons with and without AD.
Methods
Study cohort
The Medication and Alzheimer’s disease (MEDALZ)
cohort includes all community-dwelling persons who
received a new clinically verified diagnosis of AD in
2005–2011 (N = 70,719) [24]. The age range of the co-
hort was 34–105 years (mean 80.1 (SD 7.1) years) and
65.2% of the study population were women. Persons
with incident AD diagnosis were identified from the
Finnish Special Reimbursement Register maintained by
the Social Insurance Institution of Finland (SII) as de-
scribed previously [24]. The Special Reimbursement
Register contains records of all persons who are eligible
for higher reimbursement due to certain chronic dis-
eases, including AD. To be eligible for reimbursement,
the disease must be diagnosed according to specific cri-
terion and diagnosis statement must be submitted to the
SII by a physician. The AD diagnosis was mainly based
on the National Institute of Neurological and Communi-
cative Disorders and Stroke and the Alzheimer’s Disease
and Related Disorders Association’s (NINCDS-ADRDA)
and Diagnostic and Statistical Manual of Mental Disor-
ders, 4th Edition (DSM-IV) criteria for Alzheimer’s dis-
ease [25, 26]. Briefly, the criterion for AD includes 1)
symptoms consistent with mild or moderate AD, 2)
decrease in social capacity over a period of at least 3
months, 3) computer tomography (CT)/magnetic reson-
ance imaging scan (MRI) to confirm that neuroanatom-
ical changes are consistent with AD, 4) exclusion of
possible alternative diagnoses, and 5) confirmation of
the diagnosis by a registered geriatrician or neurologist.
Summary of anamnestic information from the patients
and family, as well as findings e.g. MRI/CT, laboratory
tests, and cognitive tests, are submitted to the SII, where
a geriatrician/neurologist systematically evaluates the
diagnostic evidence for each AD case and confirms
whether the pre-specified criteria are met.
To compare the hip fracture risk factors and mortality
predictors among persons with and without AD, an age,
sex- and university hospital district-matched cohort of
persons who did not have clinically verified AD diag-
nosis, was identified from a SII database, which
covers all residents of Finland who are eligible for so-
cial security. The matching was performed separately
for those without previous hip fracture prior to AD
diagnosis and those with previous history of hip frac-
ture. Main analyses were restricted to those with no
previous hip fracture before the follow-up (N =
67,072 in both cohorts, Fig. 1).
For hip fracture analyses, the follow-up for each
matched pair began on the date of AD diagnosis of the
index case and ended on the date of first incident hip
fracture during the study period, date of death or end of
the follow-up (December 31, 2012), whichever occurred
first. For mortality predictors, the follow-up began on
the date of first incident hip fracture during the follow-
up and ended on date of death or end of follow-up.
Each resident of Finland is assigned a unique personal
identity code which was used to compile the research
database from various national registers as described
previously [27]. All data were de-identified (i.e., the per-
sonal identity codes were substituted by anonymous
numerical codes) by the register maintainers before the
data were submitted to the research team. Study partici-
pants were not contacted. According to the Finnish
legislation, ethics committee approval or informed
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consent were not required. The study protocol was
approved by the register maintainers (Statistics Finland,
SII and National Institute of Health and Welfare).
Hip fracture and mortality after hip fracture
Hip fractures during 1972–2012 were identified from
the national Care Register for Health Care, based on the
International Classification of Diseases (ICD) with fol-
lowing ICD-10 codes (and corresponding ICD-9 and
ICD-8 codes): S72.0 (fracture of neck of femur), S72.1
(pertrochanteric fracture) and S72.2 (subtrochanteric
fracture). Finnish Care Register for Health Care is a
statutory register containing information on use of in-
and outpatient healthcare services. The individual-level
data are collected and updated continuously. Our study
was restricted to inpatient part of the register. A study
comparing audit and register-based data showed that
98.1% of occurred hip fractures were recorded in the in-
patient data of the Care Register for Health Care [28].
Mortality data (2005–2012) were obtained from the
Causes of Death Register, maintained by Statistics Finland.
Predictors
Socioeconomic position (SEP), defined by the occupa-
tional social class, was obtained from the censuses main-
tained by Statistics Finland. The data were collected on
five-year intervals between 1970 and 1990, on 1993,
1995, 2000, and annually from 2004 onwards. The 2010
version of the original classification is available from
reference http://www.stat.fi/meta/luokitukset/ammatti/
001-2010/index_en.html, older versions available from
authors by request). An ordinal variable with the follow-
ing categories was derived “managerial/professional”,
“office worker”, “farming/forestry”, “sales/industry/clean-
ing”, “unknown” and “did not respond”. For each indi-
vidual, the highest class from 1970 until the beginning
of the follow-up was used.
History of comorbidities before the follow-up (since
1972) were identified from the National Hospital Dis-
charge Register and Special Reimbursement Register.
Data on diabetes, cardiovascular diseases (hypertension,
coronary artery disease, familial hypercholesterolemia,
heart failure, and chronic cardiac arrhythmias) and
asthma or chronic obstructive pulmonary disease were
obtained from the Special Reimbursement Register. Data
on stroke (ICD-10 codes I60-I64), and mental and
behavioural disorders (ICD-10 codes F*) were obtained
from the National Hospital Discharge Register. In
addition, active cancer treatment within five years before
the follow-up was defined from the Hospital Discharge
register (Nordic Medico-Statistical Committee procedure
codes for radiotherapy; AAG50, AX, HA0, PJO, QA0,
QB0, QC0, QD0, QW0, QX0, WA, WB, WC, WD, WE,
WF0, WFO and ZX0) and Prescription Register (anti-
neoplastic drugs with the following ATC-codes: L01, L02,
L03AA, L03AB01, L03AB04, L03AB05, L03AC, L03AX,
L04AA10, L04AA34, L04AA18, L04AX02, L04AX03 ex-
cluding L01BA01 and L04AX03 users with rheumathoid
arthritis). Prosthetic hip and knee replacements were iden-
tified with the Finnish version of the Nordic Medico-
Statistical Committee (NOMESCO) classification for
Surgical Procedures (NCSP) using the following codes:
NFB and NFC for hip joint and NGB, NGC for knee.
Medication use was defined as medication use
within the previous five years before the date of
cohort entry. For mortality analyses, the time window
was five years before hip fracture date. Data on
medication use were obtained from the Finnish
National Prescription Register which covers reim-
bursed prescription drug purchases. All drugs in the
Prescription Register are categorised according to the
World Health Organization (WHO) Anatomical
Therapeutic Chemical (ATC) Classification system
and purchased amounts are recorded in Defined
Daily Doses (DDDs); the assumed average mainten-
ance dose per day for a drug used for its main indi-
cation in adults [29]. For each person, the drug use
periods for each ATC code have been modelled with
a validated PRE2DUP (From prescription drug pur-
chases to drug use periods) method [30]. PRE2DUP
is based on sliding averages of DDD and it accounts
for hospitalisations, stockpiling and dose changes.
Medications were identified with the following ATC-
codes; use of any cardiovascular drug (C*), drugs for
Fig. 1 Formation of study samples for hip fracture and mortality risk
factor analyses
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obstructive airway diseases (ATC code R03), anti-Parkinson
drugs (N04), estrogen and estrogen-progesterone combina-
tions (G03C and G03F), bisphosphonates (M05BA,
M05BB), proton pump inhibitors (A02BC), antiepileptic
drugs (N03), antipsychotics (N05A excluding lithium
(N05AN)), antidepressants (N06A), benzodiazepines and
benzodiazepine-related drugs (BZDRs; N05BA, N05CD
and N05CF) and opioids (N02A).
Statistical analyses
All statistical analyses were performed with Stata/MP 14.1.
Characteristics between AD and non-AD cohorts were
compared with t-test and χ2-test. Associations between
predictors and hip fracture, and predictors and death after
hip fracture were assessed with Cox regression. Propor-
tional hazards assumptions were confirmed with Schoen-
feld residuals. Main analyses were restricted to those
without previous hip fracture before cohort entry, but add-
itional sensitivity analyses among those with previous hip
fracture are presented in Additional file 1: Table S1–S3.
These analyses were conducted to assess whether the asso-
ciations were similar when persons with previous hip frac-
tures were included.
Results
Hip fracture risk factors
The follow-up time was 231,939 person-years in the AD
cohort and 269,905 person-years in the non-AD cohort.
Fig. 2 Incidence of hip fracture in a women and b men in persons with and without Alzheimer’s disease. Due to data sparsity in the youngest
and oldest age groups, the age range was restricted to 60–95 years
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The average follow-up in the AD cohort was 3.0 years
(range 1 day-8.0 years) and in the non-AD cohort 3.6
years (range 1 day-8.0 years). Altogether 5,264 hip frac-
tures occurred in the AD cohort (incidence rate 2.23 hip
fractures/100 person-years). In the non-AD cohort, the
incidence rate was 0.98 hip fractures/100 person-years
(n of fractures = 2,643). When persons with previous
fractures were excluded the incidence rates were 2.19 in
the AD cohort (n of hip fractures = 4,851) and 0.90 in
the non-AD cohort (n of hip fractures = 2,336). Persons
with AD had higher relative risk of hip fracture during
the follow-up (SEP-adjusted HR 2.35, 95% CI 2.24-2.46
when those with previous fractures were included, HR =
2.46, 95% CI 2.34-2.59 when they were excluded). The
impact of AD on hip fracture risk is illustrated in Fig. 2,
which shows that although the risk of hip fracture in-
creases steadily across aging in both AD and non-AD
cohorts (in both sexes) and the changes occur in parallel,
the incidence rate in the AD cohort remains constantly
higher.
Characteristics of AD and non-AD cohort are shown
in Table 1 and characteristics of those with previous hip
fracture in Additional file 1: Table S1. Persons in the AD
cohort experienced their hip fracture at younger age
than in the non-AD cohort. Cardiovascular diseases
(CVD), stroke, diabetes, hip and knee replacements and
any mental or behavioural disorder were more common
in the AD cohort. They were also more likely to have
CVD medication, use bisphosphonates, anti-Parkinson
drugs, antiepileptics, antipsychotics, antidepressants,
proton pump inhibitors, BZDRs or opioids than those
without AD. The differences were similar among those
with a previous hip fracture.
Regardless of risk factor category, the age- and sex-
adjusted incidence rate of hip fracture were higher in
the AD cohort (Tables 2 and 3). Higher age was associ-
ated with higher risk of hip fracture in both cohorts, but
the association was stronger in the non-AD cohort. In
general, the associations of sex and occupational social
class were of similar magnitude in both cohorts, with
the exception of the ‘Unknown’ category, that had
lower risk of hip fracture in the non-AD cohort. After
adjusting for occupational social class, history of men-
tal and behavioural disorders, having a hip or knee
replacement, use of antipsychotics and antidepressants
or anti-Parkinson drugs were related to higher risk,
and hormone therapy to lower hip fracture risk in
both cohorts. Stroke, diabetes, active cancer treat-
ment, proton pump inhibitors, antiepileptics, BZDRs
and opioids were associated with higher hip fracture
risk in the non-AD cohort only, while any CVD
medication was associated with lower risk in the AD
cohort. The results remained similar when those with
previous hip fracture were included (Additional file 1:
Table S2). Previous hip fracture was related to higher
risk of hip fracture during the follow-up and as with
other comorbidities and medications, the association
was stronger in those without AD.
Predictors of mortality after hip fracture
The median follow-up time after hip fracture was 1.3
years (range 1 day-7.7 years) in the AD cohort and 1.2
years (range 1 day-7.2 years) in the non-AD cohort. The

















Men 43158 (64.3) 43158 (64.3) matched
Women 23914 (35.7) 23914 (35.7)
Highest occupational
social class before follow-up
Managerial/professional 14072 (21.0) 14454 (21.5) <0.001
Office worker 5608 (8.4) 5629 (8.4)
Farming/forestry 12735 (19.0) 13160 (19.6)
Sales/industry/cleaning 28669 (42.7) 26180 (39.0)
Unknown 5470 (8.2) 5186 (7.7)
Did not respond 518 (0.8) 2463 (3.7)
Hip replacement 2219 (3.3) 1001 (1.5) <0.001
Knee replacement 105 (0.2) 67 (0.1) 0.004
Cardiovascular disease 34046 (50.8) 32841 (49.0) <0.001
Stroke 6356 (9.5) 5232 (7.8) <0.001
Diabetes 8969 (13.4) 7527 (11.2) <0.001
Asthma/COPD 5846 (8.7) 6011 (9.0) 0.11
Cancer treatment 792 (1.2) 855 (1.3) 0.12
Any mental or
behavioural disorder
15365 (22.9) 5917 (8.8) <0.001
Any CVD medication 57603 (85.9) 54704 (81.6) <0.001
Drugs for obstructive
airway diseases
15895 (23.7) 15991 (23.8) 0.54
Hormone therapy use 4429 (6.6) 4213 (6.3) 0.16
Bisphosphonates 8932 (13.3) 7460 (11.1) <0.001
Proton pump inhibitors 22281 (33.2) 21760 (32.4) 0.002
Anti-Parkinson drugs 2349 (3.5) 1959 (2.9) <0.001
Antiepileptics drugs 6729 (10.0) 5697 (8.5) <0.001
Antipsychotics 11127 (16.6) 5364 (8.0) <0.001
Antidepressants 23044 (34.4) 13821 (20.6) <0.001
Benzodiazepines and related
drugs
29368 (43.8) 25915 (38.6) <0.001
Opioids 28907 (43.1) 25742 (38.4) <0.001
Data are given as n (%) unless otherwise indicated
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average follow-up from hip fracture to death was 261
days (range 1 day-7.6 years) in the AD cohort and 212
days (range 1 day-7.6 years) in the non-AD cohort.
Altogether 2,407 persons with AD (49.6%) died after ex-
periencing a hip fracture, in comparison to non-AD co-
hort in which 923 persons (39.5%) of those who
experienced a hip fracture died. Persons with AD had
higher relative risk of death after hip fracture (SEP-ad-
justed HR 1.41, 95% CI 1.31-1.52). The excess risk was
similar in men and women (P for interaction 0.76), but
more pronounced among those who were diagnosed AD
at younger age (or experienced the first hip fracture at
younger age) (P for interaction <0.001). The association
was stronger among those who were <85 years old (SEP-
adjusted HR 1.72, 95% CI 1.52-1.95) than among those
who were at least 85 years old when they experienced
the fracture (adjusted HR 1.33, 95%CI 1.22-1.46).
Women and older individuals had higher risk of death
after hip fracture in both cohorts, while occupational so-
cial class was not associated with mortality after hip
fracture (Table 4). History of CVD, stroke, mental and
behavioural disorders, CVD medication, proton pump
inhibitors, antipsychotics and opioids were associated
with higher mortality risk in both cohorts but the associ-
ations were stronger in the non-AD cohort (Tables 4
and 5). Antidepressants, BZDRs, and cancer treatment
were associated with higher mortality risk in the non-
AD group while diabetes, asthma/COPD, drugs for
obstructive airway diseases and antiepileptic drugs were
related to higher mortality in the AD cohort. Persons
with knee replacement had lower risk of death in the
AD cohort. Similar associations were observed when
those with previous hip fracture were included in the
analyses (Additional file 1: Table S3), although the
Table 2 Hip fracture risk factors (demographic and comorbidities) in AD and non-AD cohorts (persons with previous fractures
excluded)
Risk factor Category AD cohort Non-AD cohort








Age at baseline, increase per year 1.07 (1.06–1.07) 1.06 (1.06–1.07) N.A 1.12 (1.11–1.12) 1.12 (1.11–1.13)
Sex Men 2.50 1.00 (reference) 1.00 (reference) 1.05 1.00 (reference) 1.00 (reference)
Women 1.58 0.63 (0.59–0.68) 0.73 (0.68–0.78) 0.64 0.61 (0.56–0.67) 0.76 (0.69–0.84)
Highest occupational social
class before follow-up
Managerial/professional 1.83 1.00 (reference) 1.00 (reference) 0.66 1.00 (reference) N.A
Office worker 2.52 1.38 (1.23–1.54) 1.17 (1.04–1.31) 0.95 1.45 (1.23–1.72)
Farming/forestry 2.05 1.12 (1.02–1.24) 0.95 (0.86–1.04) 0.94 1.45 (1.26–1.66)
Sales/industry/cleaning 2.15 1.18 (1.08–1.27) 1.04 (0.96–1.13) 0.96 1.47 (1.31–1.66)
Unknown 3.27 1.79 (1.62–1.99) 1.19 (1.06–1.32) 1.48 2.30 (1.97–2.68)
Did not respond 2.50 1.36 (1.00–1.87) 1.16 (0.85–1.58) 0.25 0.38 (0.25–0.56)
Hip replacement No 1.22 1.00 (reference) 1.00 (reference) 0.52 1.00 (reference) 1.00 (reference)
Yes 41.83 42.0 (39.5–44.6) 38.8 (36.5–41.2) 36.47 94.3 (86.4–103.0) 71.2 (65.1–77.9)
Knee replacement No 2.14 1.00 (reference) 1.00 (reference) 0.88 1.00 (reference) 1.00 (reference)
Yes 59.15 28.4 (23.4–34.4) 25.3 (20.8–30.7) 36.84 45.9 (35.9–58.6) 40.3 (31.5–51.5)
Cardiovascular disease No 2.18 1.00 (reference) 1.00 (reference) 0.83 1.00 (reference) 1.00 (reference)
Yes 2.19 1.01 (0.95–1.06) 0.94 (0.89–1.00) 0.98 1.20 (1.11–1.30) 0.99 (0.91–1.07)
Stroke No 2.18 1.00 (reference) 1.00 (reference) 0.86 1.00 (reference) 1.00 (reference)
Yes 2.30 1.06 (0.96–1.17) 1.05 (0.95–1.16) 1.42 1.67 (1.47–1.89) 1.42 (1.26–1.62)
Diabetes No 2.19 1.00 (reference) 1.00 (reference) 0.89 1.00 (reference) 1.00 (reference)
Yes 2.14 0.98 (0.90–1.06) 1.03 (0.95–1.13) 0.99 1.11 (0.98–1.26) 1.13 (0.99–1.28)
Cancer treatment No 2.19 1.00 (reference) 1.00 (reference) 0.90 1.00 (reference) 1.00 (reference)
Yes 2.06 0.94 (0.71–1.24) 1.01 (0.76–1.34) 1.31 1.44 (1.05–1.98) 1.67 (1.22–2.30)
Asthma/COPD No 2.18 1.00 (reference) 1.00 (reference) 0.90 1.00 (reference) 1.00 (reference)
Yes 2.24 1.02 (0.93–1.13) 1.03 (0.94–1.14) 0.95 1.05 (0.91–1.21) 1.07 (0.93–1.23)
Any mental or behavioural
disorder
No 2.09 1.00 (reference) 1.00 (reference) 0.85 1.00 (reference) 1.00 (reference)
Yes 2.53 1.21 (1.14–1.29) 1.16 (1.09–1.24) 1.53 1.83 (1.63–2.05) 1.71 (1.52–1.92)
aAdjusted for occupational social class
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association between cancer treatment and mortality in
the non-AD cohort was no longer evident.
Discussion
Our findings indicate that in general, the same risk fac-
tors were associated with hip fracture risk in persons
with and without AD, although the associations were
stronger among those without AD. Similar results were
observed with mortality predictors, with the exception
of knee replacements that were not associated with mor-
tality in the non-AD cohort. This different association
likely reflects patient selection for knee replacement
among persons with AD. One possible explanation is
that AD itself is such a strong risk factor for hip fracture
[3] and adverse outcomes after hip fracture [4], that it
overrules the impact of other comorbidities and risk
factors. This was illustrated in the hip fracture incidence
rate graphs: for example, the hip fracture risk of a 75-
year-old woman with AD was equal to that of an 85-
year-old women without AD. To our knowledge, this is
the first study assessing the predictors of hip fracture
and mortality after hip fracture among persons with
AD/dementia and comparing the magnitude of these
associations to those without AD. As the aim was to
compare the relative risk associated with individual pre-
dictors, the results were not adjusted for comorbidity
index. This would have also lead into severe collinearity
issues as many of the predictors (such as stroke, diabetes
and cancer) are included in most indices.
Strengths of our study include a nationwide cohort of
persons with clinically verified AD diagnosis and accur-
ately recorded hip fractures [31] and mortality. Thus,
there was no loss to follow-up bias. Studies assessing the
internal validity of Finnish Care Register for Health Care
and comparing register information with patient records
or other information from the primary source have con-
firmed that the coverage and accuracy of these registers
are well-suited for epidemiological research (reviewed in
reference [32]. The agreement between self-reported
drug use interview and drug use periods modelled from
the prescription register was very good or good for car-
diovascular drugs, drugs for obstructive airway diseases,
bisphosphonates, proton pump inhibitors, psychotropics
and opioids [33]. Hormone therapy, antiepileptics and
Table 3 Hip fracture risk factors (medications) in AD and non-AD cohorts (persons with previous fractures excluded)
Risk factor Category AD cohort Non-AD cohort








Any CVD medication No 2.21 1.00 (reference) 1.00 (reference) 0.63 1.00 (reference) 1.00 (reference)
Yes 2.18 0.99 (0.91–1.06) 0.84 (0.78–0.91) 0.98 1.54 (1.37–1.73) 1.02 (0.91–1.15)
Drugs for obstructive airway diseases No 2.21 1.00 (reference) 1.00 (reference) 0.90 1.00 (reference) 1.00 (reference)
Yes 2.11 0.96 (0.89–1.02) 0.97 (0.90–1.03) 0.92 1.01 (0.92–1.11) 1.00 (0.91–1.11)
Hormone therapy No 2.23 1.00 (reference) 1.00 (reference) 0.93 1.00 (reference) 1.00 (reference)
Yes 1.66 0.74 (0.66–0.84) 0.87 (0.77–0.98) 0.51 0.54 (0.44–0.67) 0.79 (0.64–0.98)
Bisphosphonates No 2.13 1.00 (reference) 1.00 (reference) 0.88 1.00 (reference) 1.00 (reference)
Yes 2.58 1.21 (1.12–1.31) 0.97 (0.90–1.05) 1.14 1.29 (1.14–1.46) 0.96 (0.85–1.08)
Proton pump inhibitors No 2.18 1.00 (reference) 1.00 (reference) 0.83 1.00 (reference) 1.00 (reference)
Yes 2.19 1.00 (0.94–1.07) 0.96 (0.90–1.02) 1.07 1.27 (1.17–1.39) 1.14 (1.05–1.25)
Anti-Parkinson drugs No 2.16 1.00 (reference) 1.00 (reference) 0.88 1.00 (reference) 1.00 (reference)
Yes 2.95 1.36 (1.19–1.57) 1.46 (1.27–1.68) 1.66 1.86 (1.53–2.26) 1.67 (1.38–2.03)
Antiepileptics drugs No 2.20 1.00 (reference) 1.00 (reference) 0.88 1.00 (reference) 1.00 (reference)
Yes 2.09 0.95 (0.86–1.05) 0.99 (0.90–1.09) 1.23 1.37 (1.19–1.57) 1.27 (1.11–1.46)
Antipsychotics No 2.12 1.00 (reference) 1.00 (reference) 0.85 1.00 (reference) 1.00 (reference)
Yes 2.53 1.20 (1.11–1.29) 1.12 (1.04–1.20) 1.64 1.95 (1.73–2.20) 1.56 (1.38–1.76)
Antidepressants No 2.14 1.00 (reference) 1.00 (reference) 0.83 1.00 (reference) 1.00 (reference)
Yes 2.28 1.07 (1.00–1.13) 1.06 (1.00–1.12) 1.24 1.49 (1.36–1.64) 1.34 (1.22–1.47)
BZDRS No 2.04 1.00 (reference) 1.00 (reference) 0.74 1.00 (reference) 1.00 (reference)
Yes 2.39 1.17 (1.11–1.24) 1.03 (0.97–1.09) 1.18 1.58 (1.45–1.71) 1.22 (1.12–1.32)
Opioids No 2.09 1.00 (reference) 1.00 (reference) 0.80 1.00 (reference) 1.00 (reference)
Yes 2.34 1.12 (1.05–1.18) 1.00 (0.94–1.06) 1.12 1.36 (1.25–1.48) 1.10 (1.01–1.19)
aAdjusted for occupational social class
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anti-Parkinson drugs were not included in that study,
but as these are mainly used regularly, and good or very
good agreement was observed for regularly used drugs
[33], exposure to them should also be captured from the
prescription register. We were also able to compare the
associations to persons without AD. Our sample was not
selected on the basis of socioeconomic position, which
increases the generalisability of our findings.
Our study is limited in the sense that the sample was
restricted to those who were community-dwelling at the
beginning of follow-up. Therefore the results are not en-
tirely generalisable to institutionalised persons. This re-
striction was applied because medications provided at
certain institutions are not recorded in the prescription
register and thus inclusion of institutionalised persons
would have increased the possibility of misclassification
bias. The data were obtained from national registers,
which include all purchased reimbursable medications.
Although purchased medications may not always reflect
consumed medications, our results are not prone to re-
call bias, and the dispensing data approximates the
medication use better than prescription data. Further,
data on risk factors such as smoking, bone mass density
or weight changes were not available and thus it would
be important to assess the impact of these risk factors in
future studies.
Similar to previous studies and meta-analyses, women
and older individuals had higher risk of hip fracture [12]
while men had higher mortality after experiencing a hip
fracture in both cohorts [20, 21, 23]. Stroke and cancer
(indicated by radiotherapy or antineoplastic medication)
were associated with higher risk of hip fracture in the
non-AD cohort only. In addition, there was a ten-
dency for increased hip fracture risk among those
with diabetes in the non-AD cohort, but the confi-
dence intervals included also 1. Mental and
Table 4 Predictors of mortality (demographics and comorbidities) after hip fracture (persons with previous fractures excluded)













Age at baseline, increase
per year
1.04 (1.03–1.05) 1.05 (1.05–1.06) N.A 1.07 (1.06–1.09) 1.08 (1.07–1.10)
Sex Men 25.1 1.00 (reference) 1.00 (reference) 19.4 1.00 (reference) 1.00 (reference)
Women 47.7 1.90 (1.74–2.08) 2.09 (1.90–2.29) 39.3 2.06 (1.79–2.36) 2.43 (2.10–2.80)
Highest occupational social
class before follow-up
Managerial/professional 29.9 1.00 (reference) 1.00 (reference) 23.4 1.00 (reference) N.A
Office worker 25.6 0.85 (0.72–1.01) 1.02 (0.86–1.21) 20.7 0.88 (0.66–1.16)
Farming/forestry 30.6 1.02 (0.89–1.17) 1.01 (0.88–1.15) 23.0 0.97 (0.78–1.21)
Sales/industry/cleaning 29.6 0.99 (0.88–1.11) 1.05 (0.93–1.18) 23.7 1.00 (0.83–1.22)
Unknown 28.8 0.96 (0.83–1.12) 1.04 (0.89–1.21) 24.5 1.05 (0.82–1.34)
Did not respond 25.7 0.86 (0.55–1.33) 1.03 (0.67–1.61) 23.3 0.97 (0.48–1.98)
Hip replacement No 29.36 1.00 (reference) 1.00 (reference) 23.38 1.00 (reference) 1.00 (reference)
Yes 21.85 0.74 (0.49–1.13) 0.68 (0.45–1.04) 20.36 0.86 (0.46–1.61) 1.22 (0.65–2.29)
Knee replacement No 29.62 1.00 (reference) 1.00 (reference) 23.47 1.00 (reference) 1.00 (reference)
Yes 19.88 0.67 (0.52–0.87) 0.73 (0.56–0.95) 18.83 0.80 (0.51–1.24) 0.88 (0.56–1.38)
Cardiovascular disease No 26.5 1.00 (reference) 1.00 (reference) 20.2 1.00 (reference) 1.00 (reference)
Yes 32.1 1.21 (1.12–1.32) 1.19 (1.10–1.29) 26.0 1.28 (1.12–1.47) 1.31 (1.15–1.50)
Stroke No 28.7 1.00 (reference) 1.00 (reference) 22.3 1.00 (reference) 1.00 (reference)
Yes 36.8 1.28 (1.12–1.47) 1.19 (1.03–1.37) 37.9 1.70 (1.38–2.09) 1.67 (1.35–2.06)
Diabetes No 28.7 1.00 (reference) 1.00 (reference) 23.3 1.00 (reference) 1.00 (reference)
Yes 33.3 1.16 (1.03–1.31) 1.22 (1.08–1.38) 23.9 1.03 (0.85–1.24) 1.17 (0.96–1.42)
Asthma/COPD No 28.9 1.00 (reference) 1.00 (reference) 23.5 1.00 (reference) 1.00 (reference)
Yes 33.4 1.16 (1.01–1.33) 1.17 (1.02–1.34) 22.2 0.93 (0.74–1.17) 1.04 (0.83–1.31)
Cancer treatment No 29.3 1.00 (reference) 1.00 (reference) 23.3 1.00 (reference) 1.00 (reference)
Yes 23.6 0.81 (0.52–1.24) 0.88 (0.57–1.35) 26.4 1.12 (0.68–1.83) 1.63 (0.99–2.68)
Any mental or behavioural
disorder
No 28.2 1.00 (reference) 1.00 (reference) 22.8 1.00 (reference) 1.00 (reference)
Yes 31.6 1.12 (1.03–1.22) 1.18 (1.08–1.29) 28.1 1.25 (1.02–1.54) 1.28 (1.04–1.58)
aAdjusted for occupational social class
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behavioural disorders (i.e., the entire F chapter of
ICD-10) were associated with higher risk in both co-
horts. This could in part be due to the association of
psychotropic medications, as observed in ours and
previous studies [4, 18]. Alternatively, it may also re-
flect the association between dementia and hip frac-
ture. Consistent with previous studies [4, 18, 19],
antidepressant and antipsychotic use were related to
higher risk of hip fracture in both cohorts and
BZDRs with hip fracture risk [34, 35] in the non-AD
cohort.
The majority of the identified risk factors, such as
sex, age, cancer treatment, CVD, stroke and psychi-
atric illness can essentially be considered as non-
modifiable. However, our result highlight the overall
impact of preventive efforts on e.g. dementia and
cardiovascular diseases, as the burden of these dis-
eases is not restricted to the condition per se, be-
cause they may further predispose persons to other
comorbidities such as hip fracture. Similarly, some of
the identified medications may be non-modifiable, as
these medications may be inevitably needed by the
patient. However, psychotropic medications impair
cognition and balance [36] and increase sedative load
[37], thus doubling the risk of falls among older per-
sons [38, 39].
Different preventive interventions, for falls [6] and fall-
related injuries [7, 8] have been proposed, including
exercise, medications, home safety assessment and
modification interventions, as well as medication
reviews. However, majority of these have focussed on
community-dwellers in general [7, 8, 11] and thus they
may not be directly applicable to persons with dementia,
or their uptake or effectiveness may be different in this
population. As the impact of AD in hip fracture risk ap-
pears to exceed the impact of other hip fracture risk fac-
tors, it would be important to develop and implement
measures that can be applied to this population group.
Regular medication reviews are one feasible approach. Psy-
chotropic medications increase the hip fracture risk, and
they are also widely used by persons with AD [40–42].
Thus, reducing the prescription of psychotropic
Table 5 Predictors of mortality (medications) after hip fracture in AD and non-AD cohorts (persons with previous fractures excluded)













Any CVD medication Yes 31.6 1.12 (1.03–1.22) 1.18 (1.08–1.29) 28.1 1.25 (1.02–1.54) 1.28 (1.04–1.58)
No 24.7 1.00 (reference) 1.00 (reference) 17.4 1.00 (reference) 1.00 (reference)
Yes 30.0 1.17 (1.05–1.31) 1.17 (1.04–1.31) 24.0 1.36 (1.06–1.74) 1.37 (1.07–1.76)
Drugs for obstructive airway
diseases
No 28.3 1.00 (reference) 1.00 (reference) 23.1 1.00 (reference) 1.00 (reference)
Yes 35.3 1.25 (1.12–1.39) 1.17 (1.05–1.30) 24.3 1.04 (0.88–1.23) 1.11 (0.94–1.32)
Hormone therapy No 29.8 1.00 (reference) 1.00 (reference) 23.7 1.00 (reference) 1.00 (reference)
Yes 18.6 0.63 (0.49–0.80) 0.81 (0.64–1.04) 11.7 0.50 (0.29–0.85) 0.78 (0.46–1.32)
Bisphosphonates No 29.5 1.00 (reference) 1.00 (reference) 23.7 1.00 (reference) 1.00 (reference)
Yes 28.1 0.95 (0.85–1.07) 1.07 (0.95–1.20) 21.0 0.88 (0.72–1.06) 1.06 (0.87–1.29)
Proton pump inhibitors No 26.8 1.00 (reference) 1.00 (reference) 21.0 1.00 (reference) 1.00 (reference)
Yes 33.4 1.24 (1.15–1.35) 1.25 (1.15–1.36) 26.8 1.27 (1.12–1.45) 1.31 (1.15–1.49)
Anti–Parkinson drugs No 29.28 1.00 (reference) 1.00 (reference) 23.12 1.00 (reference) 1.00 (reference)
Yes 29.10 0.99 (0.84–1.18) 1.02 (0.86–1.21) 27.15 1.18 (0.91–1.54) 1.20 (0.92–1.56)
Antiepileptics drugs No 29.0 1.00 (reference) 1.00 (reference) 23.6 1.00 (reference) 1.00 (reference)
Yes 31.9 1.10 (0.96–1.25) 1.12 (0.99–1.28) 21.2 0.90 (0.72–1.11) 0.98 (0.79–1.21)
Antipsychotics No 28.2 1.00 (reference) 1.00 (reference) 22.3 1.00 (reference) 1.00 (reference)
Yes 31.1 1.10 (1.01–1.20) 1.16 (1.06–1.26) 30.9 1.41 (1.18–1.68) 1.41 (1.18–1.68)
Antidepressants No 30.7 1.00 (reference) 1.00 (reference) 22.1 1.00 (reference) 1.00 (reference)
Yes 27.5 0.89 (0.82–0.97) 0.97 (0.89–1.05) 26.9 1.22 (1.05–1.40) 1.29 (1.11–1.48)
BZDRS No 28.4 1.00 (reference) 1.00 (reference) 21.3 1.00 (reference) 1.00 (reference)
Yes 30.2 1.06 (0.98–1.15) 1.06 (0.98–1.15) 25.7 1.21 (1.06–1.38) 1.18 (1.04–1.35)
Opioids No 25.5 1.00 (reference) 1.00 (reference) 18.7 1.00 (reference) 1.00 (reference)
Yes 32.9 1.30 (1.20–1.41) 1.29 (1.19–1.40) 28.5 1.50 (1.31–1.72) 1.56 (1.36–1.79)
aAdjusted for occupational social class
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medications by either seeking non-pharmacological alter-
natives to their use in the first place, or, for patients for
whom these medications are deemed necessary, regular
monitoring and discontinuation efforts are examples of
possible preventive measures that are hypothesised to de-
crease the incidence of falls in older population [39].
Recent systematic review suggested that antipsychotic
medication can be withdrawn from many persons with AD
and behavioural and psychological symptoms of dementia
without detrimental effects on their behaviour, although
withdrawal might not be recommended for those with
most severe symptoms [43].
Conclusions
Our results may indicate that AD itself is such a signifi-
cant hip fracture risk factor that it overrules or
diminishes the effect of other risk factors. Therefore, it
would be important to develop and implement prevent-
ive measures that are suitable for persons with AD.
Further, as our study was restricted to persons who were
community-dwelling at baseline, future studies among
institutionalised persons are needed.
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